Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 15/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14405601 | 1.00 | TRPM8 (0.40) | TRPM8HSD11B1S1PR1S1PR3KCNN4 | |
| SCHEMBL14405627 | 0.84 | TRPM8 (0.43) | TRPM8HSD11B1S1PR1S1PR3 | |
| SCHEMBL15024098 | 0.84 | TRPM8 (0.43) | TRPM8HSD11B1S1PR1S1PR3 | |
| SCHEMBL15023030 | 0.83 | GAA (0.41) | TRPM8HSD11B1 | |
| SCHEMBL14405536 | 0.83 | GAA (0.41) | TRPM8HSD11B1 | |
| SCHEMBL14334289 | 0.82 | TRPM8 (0.56) | TRPM8S1PR1S1PR3 | |
| SCHEMBL14405600 | 0.82 | TRPM8 (0.45) | TRPM8 | |
| SCHEMBL14334290 | 0.82 | TRPM8 (0.56) | TRPM8S1PR1S1PR3 | |
| SCHEMBL14407054 | 0.81 | S1PR3 (0.46) | TRPM8S1PR1S1PR3 | |
| SCHEMBL15023218 | 0.81 | S1PR3 (0.46) | TRPM8S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8710043-B2 | TRPM8 antagonists and their use in treatments | AMGEN INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885HSD11B1 4726/4885S1PR1 1275/4885 |
| US-20130157996-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | TRPM8 1/4885HSD11B1 4726/4885S1PR1 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.